Article
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA.
Cell genomics - 10 Dec 2025
Parsons Heather A, Messer Conor, Santos Katheryn, Weiss Jakob, Merrell David, Danysh Brian P, Hughes Melissa E, Kirkner Gregory J, Patel Ashka, Hess Julian, Sendrick Kerry, Stewart Chip, Grant Elizabeth, Schlueter-Kuck Kristy, Grinshpun Albert, Wagle Nikhil, Veeraraghavan Jamunarani, Leone Jose Pablo, Freedman Rachel A, Metzger Otto, Schiff Rachel, Winer Eric P, Tolaney Sara M, Rimawi Mothaffar, Krop Ian E, Getz Gad, Lin Nancy U
Abstract excerpt
Though there has been substantial progress in the development of anti-human epidermal growth factor receptor 2 (HER2) therapies to treat HER2-positive metastatic breast cancer (MBC) within the past two decades, most patients still experience disease progression and cancer-related death. HER2-directed tyrosine kinase inhibitors can be highly effective therapies for patients with HER2-positive MBC; however, an...
Read the complete abstract on PubMedTopics
- Humans
- Drug Resistance, Neoplasm
- Female
- Protein Kinase Inhibitors
